Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 18, 2022 6:26pm

195 Views

Post# 34970189

RE:RE:RE:RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

The simple answer is yes ... and the AWARE-1 study confirms this benefit using immune checkpoint inhibitors. So also think of the possibility of using pelareorep in a triple I/O combination with CA R-T therapy+ immune checkpoint inhibitors in difficult to treat cancers.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas